ValiRx Share News (VAL)

LONDON (Dow Jones)--ValiRx PLC (VAL.LN), a life science company with a focus on cancer diagnostics and therapeutics for personalized medicine, said Thursday its human papilloma virus, or HPV, smear test to detect the onset of cervical cancer in women has now begun clinical sample validation. MAIN FACTS: -To date, this molecular diagnostic test has been developed and analytically validated or proven to work in the laboratory. -A clinical study has now started to validate its diagnostic capability and reproducibility of results in women; The ValiRx test has been developed to give a clear positive or negative result as to the presence of high risk HPV subtypes which are likely to cause cervical cancer and it is testing the high risk subtypes that is the major issue for predicting the risk of cervical cancer. -Pre-clinical studies indicate that the combination of the HPV test with the Pap smear test provides close to 100% accuracy of diagnosis. -Shares on Wednesday closed at 0.33 pence, valuing the company at GBP1.1 million. -By Tapan Panchal, Dow Jones Newswires. Tel +44(0)207-842 9448, tapan.panchal@dowjones.com (END) Dow Jones Newswires July 15, 2010 02:40 ET (06:40 GMT)